Atlas Trials

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Clinical trial NCT07047365 · RECRUITING

Trial details

NCT number
NCT07047365
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
HER2-positive Advanced Breast Cancer
Start date
2025-07-25
Primary completion
2028-06-01
Enrollment
416

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.